IngentaConnect Clinical pharmacology of clemastine in healthy dogs

Authors: HANSSON H.; BERGVALL K.¹; BONDESSON U.; HEDELAND M.²; TÖRNEKE K.³

Source: Veterinary Dermatology, Volume 15, Number 3, June 2004 , pp. 152-158(7)

Abstract:

The pharmacokinetic properties of clemastine were investigated in six healthy dogs and compared with the effect of the drug recorded as inhibition of wheal formation induced by intradermal injections of histamine. Clemastine clearance was high (median: 2.1 L h^-1 kg^-1) and the volume of distribution large (13.4 L kg^-1). The half-life after intravenous administration was 3.8 h and the plasma protein binding level in vitro was 98%. After oral administration, the bioavailability was only 3%. Given intravenously, clemastine (0.1 mg kg^-1) inhibited wheal formation completely for 7 h, whereas the effect after oral administration (0.5 mg kg^-1) was minor. The data show that most dosage regimens suggested in the literature for the oral administration of clemastine to dogs are likely to give too low a systemic exposure of the drug to allow effective therapy.

Keywords: clemastine; dog; histamine; LC-MS/MS; pharmacokinetic; wheal

Document Type: Research article

DOI: 10.1111/j.1365-3164.2004.00367.x

Affiliations: 1: Department of Small Animal Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden 2: Department of Chemistry, National Veterinary Institute, Uppsala, Sweden 3: Department of Pharmacology and Toxicology, Swedish University of Agricultural Sciences, Uppsala, Sweden

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy